{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:21:41Z","timestamp":1760059301394,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The patient-reported outcomes (PROs) of sacituzumab govitecan (SG) were compared with chemotherapy using two phase 3 trials (TROPiCS-02, EVER-132-002) involving patients with HR+\/HER2\u2212 locally recurrent inoperable or metastatic breast cancer. Methods: A meta-analysis was performed to compare change from baseline (CFB) scores and time-to-deterioration (TTD) between SG and chemotherapy using EORTC QLQ-C30 and EQ-5D-5L VAS in the overall, prior CDK4\/6i-treated, and fast-progressor populations. Results of CFB and TTD analyses were summarized using hazard ratio (HR) and mean difference measures. Results: Statistically significant improvement (p &lt; 0.05) in CFB scores was observed with SG over chemotherapy in five EORTC QLQ-C30 domains: physical (mean difference: 2.64), role functioning (mean difference: 2.70), fatigue (mean difference: \u22122.51), pain (mean difference: \u22123.25) and dyspnea (mean difference: \u22123.27), and EQ-5D-5L VAS (mean difference: 1.58). In the overall population, longer TTD (p &lt; 0.05) was observed with SG versus chemotherapy on six domains of EORTC QLQ-C30: GHS\/QoL (HR: 0.76), physical (HR: 0.72), emotional functioning (HR: 0.73), fatigue (HR: 0.80), pain (HR: 0.82), and dyspnea (HR: 0.71). Results from EORTC QLQ-C30 domains were mostly consistent among the overall, prior CDK4\/6i treated and fast-progressor populations. SG demonstrated longer TTD (p &lt; 0.05) over chemotherapy for EQ-5D-5L-VAS across all studied populations (HR range: 0.63\u20130.69). PROs significantly worsened with SG in the domains of diarrhea and nausea and vomiting (commonly reported adverse events of SG, manageable by following established guidelines). Conclusions: SG significantly improved PROs versus chemotherapy for several subdomains of EORTC QLQ-C30 and EQ-5D-5L-VAS. The consistency of these results in the overall population and subgroups supports the generalizability of the meta-analytic evidence and reinforces the PRO benefits associated with SG versus chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers17111885","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:51:04Z","timestamp":1749027064000},"page":"1885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician\u2019s Choice in Previously Treated HR+\/HER\u2212 mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":false,"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandaroop","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Kaushik","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Verret","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharmacoevidence, London SE1 0AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Phung, M.T., Tin Tin, S., and Elwood, J.M. (2019). Prognostic models for breast cancer: A systematic review. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5442-6"},{"key":"ref_2","unstructured":"National Breast Cancer Foundation Inc. (2024, November 19). Breast Cancer Facts & Stats. Available online: https:\/\/www.nationalbreastcancer.org\/breast-cancer-facts\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Elfgen, C., and Bjelic-Radisic, V. (2021). Targeted therapy in HR+ HER2- metastatic breast cancer: Current clinical trials and their implications for CDK4\/6 inhibitor therapy and beyond treatment options. Cancers, 13.","DOI":"10.3390\/cancers13235994"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/oncolo\/oyae088","article-title":"Health-related quality of life with sacituzumab govitecan in HR+\/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial","volume":"29","author":"Rugo","year":"2024","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2\u2212 metastatic breast cancer: The randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: A phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2\u2212 metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol."},{"key":"ref_10","unstructured":"Dai, M.S., Xu, B., Ma, F., Wang, S., Yan, M., Li, W., Tang, J., Wang, X., Wang, Y., and Im, S.-A. (2024, January 25\u201327). Health-related quality of life (HRQOL) in the EVER-132-002 study of sacituzumab govitecan (SG) vs. treatment of physician\u2019s choice (TPC) in Asian patients with HR+\/HER2\u2212 MBC. Proceedings of the Global Breast Cancer Conference (GBCC), Seoul, Republic of Korea."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: The PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","unstructured":"(2023). Sacituzumab Govitecan: Primary Clinical Study Report: EVER-132-002. Data on File, Gilead Sciences Inc."},{"key":"ref_14","unstructured":"(2022). Sacituzumab Govitecan: Interim Clinical Study Report TROPiCS-02. Data on File, Gilead Sciences Inc."},{"key":"ref_15","unstructured":"(2022). Sacituzumab Govitecan: Primary Clinical Study Report TROPiCS-02. Data on File, Gilead Sciences Inc."},{"key":"ref_16","unstructured":"(2023). Dossier zur Nutzenbewertung Gem\u00e4\u00df \u00a7 35a SGB V. Sacituzumab Govitecan (Trodelvy\u00ae), Gilead Sciences GmbH."},{"key":"ref_17","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D.M., and Higgins, J.P.T. (2014). Evaluating the quality of evidence from a network meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099682"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111537","DOI":"10.1016\/j.jclinepi.2024.111537","article-title":"Network meta-analysis: A powerful tool for clinicians, decision-makers, and methodologists","volume":"176","author":"Florez","year":"2024","journal-title":"J. Clin. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cope, S., Zhang, J., Saletan, S., Smiechowski, B., Jansen, J.P., and Schmid, P. (2014). A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-93"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jclinepi.2010.11.016","article-title":"A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners","volume":"64","author":"Fisher","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_22","unstructured":"(2021). Protocol: IMMU-132-09 Phase 3 Study of Sacituzumab Govitecan (IMMU-132) in Relapsed\/Refractory HR+\/HER2\u2212 MBC. Data on File, Immunomedics."},{"key":"ref_23","first-page":"155","article-title":"EuroQol-5D (EQ-5D): An instrument for measuring quality of life","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch. Chest. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tierney, J.F., Vale, C., Riley, R., Smith, C.T., Stewart, L., Clarke, M., and Rovers, M. (2015). Individual participant data (IPD) meta-analyses of randomised controlled trials: Guidance on their use. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001855"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: Rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/eb-2014-101794","article-title":"How to interpret meta-analysis models: Fixed effect and random effects meta-analyses","volume":"17","author":"Nikolakopoulou","year":"2014","journal-title":"Evid. Based Ment. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103215","DOI":"10.1016\/j.esmoop.2024.103215","article-title":"193P Efficacy of sacituzumab govitecan versus treatment of physician\u2019s choice in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials","volume":"9","author":"Gluz","year":"2024","journal-title":"ESMO Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.1016\/j.annonc.2022.07.256","article-title":"217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)","volume":"33","author":"Ueno","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2024.42.16_suppl.1006","article-title":"Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study","volume":"42","author":"Pernas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105918","DOI":"10.1016\/j.ijsu.2021.105918","article-title":"PRISMA 2020 statement: What\u2019s new and the importance of reporting guidelines","volume":"88","author":"Sohrabi","year":"2021","journal-title":"Int. J. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: One-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1136\/bmjspcare-2022-003642","article-title":"Global quality of life in breast cancer: Systematic review and meta-analysis","volume":"13","author":"Raoofi","year":"2023","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ge, I., Berner, K., Mathis, M., Hensgen, C., Mayer, S., Erbes, T., Juhasz-B\u00f6ss, I., and Asberger, J. (2024). Real-world data analysis of CDK4\/6 inhibitor therapy-a patient-centric single center study. Cancers, 16.","DOI":"10.3390\/cancers16091760"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kassianos, A.P. (2022). Cross-cultural considerations in health-related quality of life in cancer. Handbook of Quality of Life in Cancer, Springer International Publishing.","DOI":"10.1007\/978-3-030-84702-9"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102165","DOI":"10.1016\/j.ejon.2022.102165","article-title":"Cultural factors affecting the self-care of cancer survivors: An integrative review","volume":"59","author":"Yeom","year":"2022","journal-title":"Eur. J. Oncol. Nurs."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:29Z","timestamp":1760031989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17111885"],"URL":"https:\/\/doi.org\/10.3390\/cancers17111885","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}